Company intelligence / Profile preview

Reveal Genomics

Barcelona, Catalonia, Spain

Ownership: Private
Development stage: Other

Overview

Reveal Genomics has validated and commercialized the HER2DX test to stratify early-stage HER2-positive breast cancer patients and predict outcomes, with real-world and clinical validation occurring in Europe and ongoing studies in the US. Their platform is expanding into liquid biopsy and novel biomarker discovery for precision oncology[5][3].

Therapeutic areas: Oncology
Modalities: In vitro diagnosticMachine learning-based biomarker platformLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

Ona Therapeutics (collaboration on ONA-255 ADC trials and biomarker/companion diagnostics development)[1]Dana-Farber Cancer Institute (US clinical study of HER2DX)[5]

Beyond the preview

Go deeper on Reveal Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reveal Genomics.

Explore the full profile